VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516181-11-00

Acronym

VALYM

Enrollment

140

Registered

2024-09-13

Start date

2021-06-10

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RELAPSE/REFRACTORY B-CELL LYMPHOMA.

Brief summary

overall response rate (ORR) defined as the proportion of subjects achieving best overall response of partial response (PR) or complete response (CR) at any time, according to the Lugano 2014 classification (PET-CT–Based Response for FDG-avid lymphomas or CT-Based Response if not) and determined by investigator.

Detailed description

- Rate of complete response (CR), - Progression-free survival (PFS), - Duration of response (DOR), - Time to response (TTR), - Safety

Interventions

DRUGValemetostat Tosylate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
overall response rate (ORR) defined as the proportion of subjects achieving best overall response of partial response (PR) or complete response (CR) at any time, according to the Lugano 2014 classification (PET-CT–Based Response for FDG-avid lymphomas or CT-Based Response if not) and determined by investigator.	—

Secondary

Measure	Time frame
- Rate of complete response (CR), - Progression-free survival (PFS), - Duration of response (DOR), - Time to response (TTR), - Safety	—

Countries

Belgium, France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026